Fusion Antibodies PLC Holding(s) in Company (9445O)

TIDMFAB

RNS Number : 9445O

Fusion Antibodies PLC

12 February 2021

Fusion Antibodies plc

("Fusion" or the "Company")

Holding in Company

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has been advised that, following a share purchase on 11 February 2021, Paul Warwick holds 814,080 ordinary shares in the Company, representing 3.2 per cent. of the Company's issued share capital.

Enquiries:

 
 Fusion Antibodies plc                                                  www.fusionantibodies.com 
 Dr Paul Kerr, Chief Executive Officer                                           Via Walbrook PR 
 James Fair, Chief Financial Officer 
 
 Allenby Capital Limited                                                Tel: [phone] 
 James Reeve / Asha Chotai (Corporate 
  Finance) 
 Tony Quirke (Sales and Corporate Broking) 
 
 Walbrook PR                                   Tel: [phone] or [e-mail] 
 Anna Dunphy                                                            Mob: [phone] 
 Paul McManus                                                           Mob: [phone] 
 
 

About Fusion Antibodies plc

Fusion is a Belfast based biotechnology company providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx (TM) platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects for its international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

Fusion is a Collaborative Research Organisation (CRO) which provides antibody discovery, engineering and supply, through to cell line development. At every stage, our client's vision is central to how we work, ensuring the best molecule goes to the clinic. Our world-class humanization and antibody optimization platforms harness the power of the natural diversity of antibodies. To address remaining market needs in antibody discovery, Fusion is creating a fully human antibody library to capture the entire human antibody repertoire.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster and ultimately speed up the drug development process.

The global monoclonal antibody therapeutics market was valued at $95.5 billion in 2017 and is forecast to surpass $174.2 billion in 2026, an increase at a CAGR of 6.9 per cent. for the period 2018 to 2026. In 2018, seven of the world's ten top selling drugs were antibody-based therapeutics with the combined annual sales of these drugs exceeding $62 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

HOLGPUUUPUPGUBP

(END) Dow Jones Newswires

February 12, 2021 04:05 ET (09:05 GMT)